Certolizumab Pegol (CDP870) 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	AntibodyLimited DatastalePhase 3 CDP870 (Certolizumab Pegol, Certolizumab Pegol (CDP870)) UCB Pharma·Crohn's Disease 57 trials

Overview Program	Certolizumab Pegol (CDP870)
Overview Company	UCB Pharma
Overview Modality	ANTIBODY
Overview Target	Crohn's Disease
Overview Indication	Crohn's Disease
Overview Phase	PHASE_3
Overview Status	ACTIVE
Overview Content status	Limited Data
Overview Data Confidence	Editorial scope · limited data
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

MoA Mechanism	Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway
MoA Biomarker	biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before a

Clinical Program phase	PHASE_3

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	AntibodyLimited DatastalePhase 3 CDP870 (Certolizumab Pegol, Certolizumab Pegol (CDP870)) UCB Pharma·Crohn's Disease 57 trials

Overview Program	Certolizumab Pegol (CDP870)
Overview Company	UCB Pharma
Overview Modality	ANTIBODY
Overview Target	Crohn's Disease
Overview Indication	Crohn's Disease
Overview Phase	PHASE_3
Overview Status	ACTIVE
Overview Content status	Limited Data
Overview Data Confidence	Editorial scope · limited data
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

MoA Mechanism	Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway
MoA Biomarker	biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before a

Clinical Program phase	PHASE_3